1. Avastin-H/C/000582-II/65 (2014) European Public Assessment Report. The European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 . Accessed 20 Aug 2014
2. Final Labeling Text, BLA 125085 (2013) Center for Drug Evaluation and Research. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s285lbl.pdf . Accessed 20 Aug 2014
3. Avastin® (2014) Genentech USA, Inc. http://www.avastin.com/patient?cid=gne_WE_00000083 . Accessed 20 Aug 2014
4. Parikh SS, Mehta HH, Desai BI (2012) Advances in development of bevacizumab, a humanized antiangiogenic therapeutic monoclonal antibody targeting VEGF in cancer cells. Int J Pharm Biomed Sci 3:155–163
5. Tabrizi M, Roskos LK (2006) Exposure–response relationships for therapeutic biologic products. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs. Principles and case studies in drug development. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 295–327